Literature DB >> 33826575

Increased 68Ga-FAPI-04 Uptake in Schmorl Node in a Patient With Gastric Cancer.

Rong Lin1, Zefang Lin, Jiaying Zhang, Shaobo Yao, Weibing Miao.   

Abstract

ABSTRACT: A 78-year-old man with a newly diagnosed gastric adenocarcinoma underwent 18F-FDG and 68Ga-FAPI-04 PET/CT before treatment. Both 18F-FDG and 68Ga-FAPI-04 PET/CT demonstrated intense radioactivity in the gastric cancer. However, the benign Schmorl node in the inferior endplate of the T5 vertebrae showed increased uptake of 68Ga-FAPI-04, which was not FDG avid. Two months after radical gastrectomy of the gastric cancer (pT1aN0M0, IA), a follow-up CT showed that the Schmorl node in T5 vertebrae remained unchanged.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID： 33826575     DOI： 10.1097/RLU.0000000000003623

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  7 in total

1.  Comparison of Diagnostic Efficacy of [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT for Staging and Restaging of Gastric Cancer.

Authors:  Shumao Zhang; Wei Wang; Tingting Xu; Haoyuan Ding; Yi Li; Huipan Liu; Yinxue Huang; Lin Liu; Tao Du; Yan Zhao; Yue Chen; Lin Qiu
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

Review 2.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

3.  Pitfalls and Common Findings in 68Ga-FAPI PET: A Pictorial Analysis.

Authors:  Lukas Kessler; Justin Ferdinandus; Nader Hirmas; Fadi Zarrad; Michael Nader; David Kersting; Manuel Weber; Sandra Kazek; Miriam Sraieb; Rainer Hamacher; Katharina Lueckerath; Lale Umutlu; Wolfgang P Fendler; Christoph Rischpler
Journal:  J Nucl Med       Date:  2021-10-07       Impact factor: 11.082

4.  Comparison of the Relative Diagnostic Performance of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/CT for the Detection of Bone Metastasis in Patients With Different Cancers.

Authors:  Junhao Wu; Yingwei Wang; Taiping Liao; Zijuan Rao; Weidong Gong; Lei Ou; Yue Chen; Chunyin Zhang
Journal:  Front Oncol       Date:  2021-09-17       Impact factor: 6.244

5.  Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

Authors:  Hessamoddin Roustaei; Zahra Kiamanesh; Emran Askari; Ramin Sadeghi; Kamran Aryana; Giorgio Treglia
Journal:  Contrast Media Mol Imaging       Date:  2022-02-22       Impact factor: 3.161

Review 6.  FAPI PET versus FDG PET, CT or MRI for Staging Pancreatic-, Gastric- and Cholangiocarcinoma: Systematic Review and Head-to-Head Comparisons of Diagnostic Performances.

Authors:  Sophie E M Veldhuijzen van Zanten; Kay J Pieterman; Bas P L Wijnhoven; Ilanah J Pruis; Bas Groot Koerkamp; Lydi M J W van Driel; Frederik A Verburg; Maarten G J Thomeer
Journal:  Diagnostics (Basel)       Date:  2022-08-12

Review 7.  FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors.

Authors:  Tianshuo Yang; Long Ma; Haodong Hou; Feng Gao; Weijing Tao
Journal:  Front Oncol       Date:  2022-01-04       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.